Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis

Tumour heterogeneity refers to the fact that different tumour cells can show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, metabolism, motility, proliferation and metastatic potential. This phenomenon occurs both between tumours (inter-tumour heterogeneity) and within tumours (intra-tumour heterogeneity), and it is caused by genetic and non-genetic factors. The heterogeneity of cancer cells introduces significant challenges in using molecular prognostic markers as well as for classifying patients that might benefit from specific therapies. Thus, research efforts for characterizing heterogeneity would be useful for a better understanding of the causes and progression of disease. It has been suggested that the study of heterogeneity within Circulating Tumour Cells (CTCs) could also reflect the full spectrum of mutations of the disease more accurately than a single biopsy of a primary or metastatic tumour. In previous years, many high throughput methodologies have raised for the study of heterogeneity at different levels (i.e., RNA, DNA, protein and epigenetic events). The aim of the current review is to stress clinical implications of tumour heterogeneity, as well as current available methodologies for their study, paying specific attention to those able to assess heterogeneity at the single cell level.

[1]  Nithya Ramnath,et al.  Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection , 2016, Cancers.

[2]  B. Nielsen,et al.  Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer , 2016, PloS one.

[3]  Fiona Ginty,et al.  Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. , 2016, JCI insight.

[4]  Mehmet Toner,et al.  Clusters of circulating tumor cells traverse capillary-sized vessels , 2016, Proceedings of the National Academy of Sciences.

[5]  F. Tang,et al.  Single-cell sequencing in stem cell biology , 2016, Genome Biology.

[6]  Jun S. Song,et al.  Intratumoral Heterogeneity of the Epigenome. , 2016, Cancer cell.

[7]  D. Heymann,et al.  Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. , 2016, Clinical chemistry.

[8]  A. Vannucchi,et al.  Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer , 2016, Oncotarget.

[9]  W. Koh,et al.  Single-cell genome sequencing: current state of the science , 2016, Nature Reviews Genetics.

[10]  Florian Engert,et al.  Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency , 2015, Nature Communications.

[11]  Shuang Hou,et al.  A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer , 2015, Oncotarget.

[12]  D. Weitz,et al.  Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state , 2015, Nature Biotechnology.

[13]  C. Swanton,et al.  The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  J. Luo,et al.  Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Franziska Michor,et al.  In situ single cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2+ breast cancer , 2015, Nature Genetics.

[16]  Carlos Caldas,et al.  Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts. , 2015, Cancer research.

[17]  Ash A. Alizadeh,et al.  Toward understanding and exploiting tumor heterogeneity , 2015, Nature Medicine.

[18]  X. Zhuang,et al.  Spatially resolved, highly multiplexed RNA profiling in single cells , 2015, Science.

[19]  D. Planchard,et al.  High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Peng Qiu,et al.  Single‐cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3‐ITD‐mutated AML stem/progenitor cells , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[21]  M. Pestrin,et al.  Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients , 2015, Molecular oncology.

[22]  Michael Kerger,et al.  Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer , 2015, Nature Communications.

[23]  B. Lim,et al.  Non‐invasive sensitive detection of KRAS and BRAF mutation in circulating tumor cells of colorectal cancer patients , 2015, Molecular oncology.

[24]  M. Nykter,et al.  The Evolutionary History of Lethal Metastatic Prostate Cancer , 2015, Nature.

[25]  Nathan C. Sheffield,et al.  Single-Cell DNA Methylome Sequencing and Bioinformatic Inference of Epigenomic Cell-State Dynamics , 2015, Cell reports.

[26]  Kun Zhang,et al.  Fluorescent in situ sequencing (FISSEQ) of RNA for gene expression profiling in intact cells and tissues , 2015, Nature Protocols.

[27]  Jin-Ling Tang,et al.  Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases , 2015, Scientific Reports.

[28]  S. Beck,et al.  Analysis pipelines and packages for Infinium HumanMethylation450 BeadChip (450k) data , 2015, Methods.

[29]  Siddharth S. Dey,et al.  Integrated genome and transcriptome sequencing from the same cell , 2014, Nature Biotechnology.

[30]  Christopher J. Sevinsky,et al.  Emerging Understanding of Multiscale Tumor Heterogeneity , 2014, Front. Oncol..

[31]  W. Koh,et al.  Dissecting the clonal origins of childhood acute lymphoblastic leukemia by single-cell genomics , 2014, Proceedings of the National Academy of Sciences.

[32]  Klaus Pantel,et al.  Biology, detection, and clinical implications of circulating tumor cells , 2014, EMBO molecular medicine.

[33]  V. Georgoulias,et al.  PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer , 2014, Clinical Cancer Research.

[34]  Nicolò Manaresi,et al.  Molecular profiling of single circulating tumor cells with diagnostic intention , 2014, EMBO molecular medicine.

[35]  Massimo Cristofanilli,et al.  CTC enumeration and characterization: moving toward personalized medicine. , 2014, Annals of translational medicine.

[36]  Laura Austin,et al.  TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients , 2014, Breast Cancer Research.

[37]  N. Navin Cancer genomics: one cell at a time , 2014, Genome Biology.

[38]  E. Rappaport,et al.  Dielectrophoretic Capture and Genetic Analysis of Single Neuroblastoma Tumor Cells , 2014, Frontiers in Oncology.

[39]  A. Saliba,et al.  Single-cell RNA-seq: advances and future challenges , 2014, Nucleic acids research.

[40]  Sridhar Ramaswamy,et al.  Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility , 2014, Science.

[41]  Mark Cobbold,et al.  Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study , 2014, PLoS biology.

[42]  J. Reis-Filho,et al.  Breast cancer intra-tumor heterogeneity , 2014, Breast Cancer Research.

[43]  C. Couldrey,et al.  Exploring genome wide bisulfite sequencing for DNA methylation analysis in livestock: a technical assessment , 2014, Front. Genet..

[44]  Eric Baudin,et al.  Integrated genomic characterization of adrenocortical carcinoma , 2014, Nature Genetics.

[45]  Timothy B Lannin,et al.  Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis. , 2014, Lab on a chip.

[46]  Klaus Pantel,et al.  [The circulating tumor cells: liquid biopsy of cancer]. , 2014, Klinicheskaia laboratornaia diagnostika.

[47]  K. Pantel,et al.  Technologies for detection of circulating tumor cells: facts and vision. , 2014, Lab on a chip.

[48]  X. Xie,et al.  Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients , 2013, Proceedings of the National Academy of Sciences.

[49]  D. Hayes,et al.  Circulating tumour cells: insights into tumour heterogeneity , 2013, Journal of internal medicine.

[50]  Wainer Zoli,et al.  Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs. , 2013, Cancer letters.

[51]  S. Sleijfer,et al.  KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue , 2013, International journal of cancer.

[52]  M. Fang,et al.  Genomic Profiling Defines Subtypes of Prostate Cancer with the Potential for Therapeutic Stratification , 2013, Clinical Cancer Research.

[53]  Peter Ulz,et al.  Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. , 2013, Cancer research.

[54]  Kornelia Polyak,et al.  Cellular heterogeneity and molecular evolution in cancer. , 2013, Annual review of pathology.

[55]  L. Pusztai,et al.  Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.

[56]  S. Kobayashi,et al.  Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[57]  A. Viale,et al.  Comparative genomic analysis of primary versus metastatic colorectal carcinomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  T. Mok,et al.  EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. , 2012, The oncologist.

[59]  G. Botti,et al.  BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Gyan Bhanot,et al.  Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines , 2012, PloS one.

[61]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[62]  Jorge S Reis-Filho,et al.  Genetic heterogeneity and cancer drug resistance. , 2012, The Lancet. Oncology.

[63]  Huanming Yang,et al.  Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor , 2012, Cell.

[64]  J. Dannenberg,et al.  Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[65]  J. Feliu,et al.  Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. , 2012, Current cancer drug targets.

[66]  T. Saida,et al.  Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level , 2012, British Journal of Cancer.

[67]  P. V. van Diest,et al.  Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment , 2011, Clinical Cancer Research.

[68]  Stephanie Alexander,et al.  Cancer Invasion and the Microenvironment: Plasticity and Reciprocity , 2011, Cell.

[69]  K. Polyak,et al.  The microenvironment in breast cancer progression: biology and implications for treatment , 2011, Breast Cancer Research.

[70]  G. Nolan,et al.  Association of Reactive Oxygen Species-Mediated Signal Transduction with In Vitro Apoptosis Sensitivity in Chronic Lymphocytic Leukemia B Cells , 2011, PloS one.

[71]  Sean C. Bendall,et al.  Extracting a Cellular Hierarchy from High-dimensional Cytometry Data with SPADE , 2011, Nature Biotechnology.

[72]  Fabrice Merenda,et al.  Microfluidic array cytometer based on refractive optical tweezers for parallel trapping, imaging and sorting of individual cells. , 2011, Lab on a chip.

[73]  Nicholas Navin,et al.  Future medical applications of single-cell sequencing in cancer , 2011, Genome Medicine.

[74]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[75]  A. Oudenaarden,et al.  Validating transcripts with probes and imaging technology , 2011, Nature Methods.

[76]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[77]  Jane E. Visvader,et al.  Cells of origin in cancer , 2011, Nature.

[78]  M. Esteller,et al.  Aberrant epigenetic landscape in cancer: how cellular identity goes awry. , 2010, Developmental cell.

[79]  Franziska Michor,et al.  The Origins and Implications of Intratumor Heterogeneity , 2010, Cancer Prevention Research.

[80]  M. Esteller,et al.  Epigenetic modifications and human disease , 2010, Nature Biotechnology.

[81]  T. Graeber,et al.  Integrated Systems and Technologies Cancer Research A Microfluidic Platform for Systems Pathology : Multiparameter Single-Cell Signaling Measurements of Clinical Brain Tumor Specimens , 2010 .

[82]  J. Nevins,et al.  Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies , 2010, Journal of Molecular Medicine.

[83]  Ash A. Alizadeh,et al.  B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression , 2010, Proceedings of the National Academy of Sciences.

[84]  A. Nassar,et al.  Intratumoral Heterogeneity of Immunohistochemical Marker Expression in Breast Carcinoma: A Tissue Microarray-based Study , 2010, Applied immunohistochemistry & molecular morphology : AIMM.

[85]  Y. Kimura,et al.  Developments and applications of mass microscopy , 2010, Medical Molecular Morphology.

[86]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[87]  M. Gönen,et al.  Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. , 2010, The Journal of clinical investigation.

[88]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[89]  O. Ornatsky,et al.  Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry. , 2009, Analytical chemistry.

[90]  Jonathan M Irish,et al.  Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. , 2008, Cancer cell.

[91]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[92]  M. Wicha Cancer stem cell heterogeneity in hereditary breast cancer , 2008, Breast Cancer Research.

[93]  Marc Ladanyi,et al.  Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases , 2008, Clinical Cancer Research.

[94]  R. Place,et al.  MicroRNA-373 induces expression of genes with complementary promoter sequences , 2008, Proceedings of the National Academy of Sciences.

[95]  Michael R. Speicher,et al.  High resolution array-CGH analysis of single cells , 2006, Nucleic acids research.

[96]  A. Lichtenstein Clonal heterogeneity of tumor may be due to continuous influx of newly transformed cells , 2006, Cancer biology & therapy.

[97]  P. Steeg Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[98]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[99]  B. Ylstra,et al.  Microarray‐based comparative genomic hybridization and its applications in human genetics , 2004, Clinical genetics.

[100]  D. Pinkel,et al.  High‐resolution genomic profiling of occult micrometastatic tumor cells , 2003, Genes, chromosomes & cancer.

[101]  J. Köllermann,et al.  Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[102]  Adrian E. Raftery,et al.  Model-based clustering and data transformations for gene expression data , 2001, Bioinform..

[103]  Anthony J. Guidi,et al.  Association of angiogenesis in lymph node metastases with outcome of breast cancer. , 2000, Journal of the National Cancer Institute.

[104]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[105]  I. Fidler,et al.  Biological diversity in metastatic neoplasms: origins and implications. , 1982, Science.

[106]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[107]  U. Demirci,et al.  KRAS discordance between primary and metastatic tumor in patients with metastatic colorectal carcinoma. , 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[108]  K. Pantel,et al.  Whole Genome Amplification in Genomic Analysis of Single Circulating Tumor Cells. , 2015, Methods in molecular biology.

[109]  L. Esserman,et al.  Expression profiling of circulating tumor cells in metastatic breast cancer , 2014, Breast Cancer Research and Treatment.

[110]  J. Izbicki,et al.  Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. , 2013, Clinical chemistry.

[111]  J. Flanagan,et al.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.

[112]  V. Chekhun,et al.  [Evaluation of biological effects and possible mechanisms of action of static magnetic field]. , 2012, Fiziolohichnyi zhurnal.

[113]  M. Herlyn,et al.  Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. , 2012, Advances in pharmacology.

[114]  Chekhun Vf,et al.  Evaluation of biological effects and possible mechanisms of action of static magnetic field , 2012 .

[115]  Donald Wlodkowic,et al.  Rise of the micromachines: microfluidics and the future of cytometry. , 2011, Methods in cell biology.

[116]  J. Salk Clonal evolution in cancer , 2010 .

[117]  J. Shipley,et al.  Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays , 2008, Nature Protocols.

[118]  G. Dakubo,et al.  Clinical implications and utility of field cancerization , 2007, Cancer Cell International.